Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.

Maria Di Bartolomeo,Roberto Buzzoni,Luigi Mariani,Erminia Ferrario,Dotti Katia,Arpine Gevorgyan,Nicoletta Zilembo,Roberto Bordonaro,Anna Maria Bochicchio,B. Massidda,Antonio Ardizzoni,Giovanni Marini,Enrico Aitini,Giuseppe Schieppati,G. Comella,Graziella Pinotti,Salvatore Palazzo,Giovanni Cicero,Emilio Bajetta

Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.

2006

Maria Di Bartolomeo
Roberto Buzzoni
Luigi Mariani
Erminia Ferrario
Dotti Katia
Arpine Gevorgyan
Nicoletta Zilembo
Roberto Bordonaro
Anna Maria Bochicchio
B. Massidda
Antonio Ardizzoni
Giovanni Marini
Enrico Aitini
Giuseppe Schieppati
G. Comella
Graziella Pinotti
Salvatore Palazzo
Giovanni Cicero
Emilio Bajetta

Objective: Combination therapies of fluorouracil (FU) with irinotecan (CPT-11) and docetaxel plus cisplatin have been proven to be active in metastatic gastric cancer. In this paper

Keywords:

FOLFIRI
Fluorouracil
Pathology
Stomach cancer
Cisplatin
Oncology
Irinotecan
Combination therapy
Medicine
Chemotherapy
Docetaxel
Internal medicine
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations